Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (4) : 459-462     DOI: 10.1007/s11684-009-0084-8
Research articles |
Epidemiological studies of women under age 30 infected with human papillomavirus
Zhihua LIU MD,Qing LI BM,Weihong LI BM,
Cervical Disease Diagnosis and Treatment of Maternal and Child Health Centers, Shenzhen Hospital, Southern Medical University, Shenzhen 518028, China;
Download: PDF(81 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  The aim of this paper was to investigate the prevalence of human papilloma virus (HPV) infection in women under 30 years old with cervical intraepithelial neoplasia (CIN) or cervical cancer, in order to provide a basis for cervical cancer prevention and treatment. We recruited 2052 female cases from the education system in Futian District, Shenzhen city, from April 2006 to April 2008, with age ranging from 22 to 60 years old. Second-generation hybrid capture test was done for detection of female genital tract HPV and cervical colposcopy for screening CIN or cervical cancer. The prevalence of HPV and cervical precancerous lesions or cervical cancer was evaluated in different age groups of women. The HPV positive rate was 247/2052 (12.00%), and 35/2052 (1.71%) of the cases were≥CIN I by pathological diagnosis. In the 22―29-year-old age group, there were 291 cases, including 39HPV-positive cases (13.40%) and one case of pathological diagnosis≥CIN I (0.34%), and there were 1761 cases in the 30―60-year-old age group, including 208 HPV-positive cases (11.81%) and 34 cases of pathological diagnosis≥CIN I (1.93%). The HPV-positive rate of 22―29-year-old age group was higher than that of 30―60-year-old age group, but the difference was not significant (χ2 = 0.5967, P = 0.4398); the CIN and cervical cancer detection rate of the former group was lower than that of the latter one, and the difference was not significant either (χ2 = 3.7519, P = 0.0527). The cases in 30―60-year-old age group were divided into five age sub-groups, and the HPV-positive rate of the 22―29-year-old age group was compared with the remaining groups, and it was found that the HPV-positive rate of the former group (13.40%) was lower than that of the 40―44-year-old age group (14.70%) but higher than that of the other four groups. Moreover, the difference in the HPV-positive rate between the 22―29-year-old age group and the 50―60-year-old age group (6.06%) was significant (χ2 = 5.545, P = 0.018), but the difference between the 22― 29-year-old age group and each of the other four groups was not significant (P>0.05). In addition, the CIN and cervical cancer detection rate of the 22―29-year-old age group (0.34%) was lower than that of the remaining five groups, and the difference between the 22―29-year-old age group and the 35―39-year-old age group (2.26%), and between 22―29-year-old age group and 40―44-year-old age group (2.30%) was significant (χ2 = 4.446, P = 0.0035; χ2 = 4.525, P = 0.0363, respectively), but the difference between the 22―29-year-old age group and each of other three groups was not significant (P>0.05). Furthermore, 80.00% (28/35) cases of pathological diagnosis≥CIN I and 90.91% (10/11) lesions of pathological diagnosis≥CIN II occurred at 35―49 years of age. For many young women below the age of 30 who were infected with high-risk HPV were one-off infections, so it was not appropriate to recommend HPV detection as cervical precancerous lesions or cancer screening program for women less than 30 years old. The prevention and treatment of cervical cancer should be focused on those women more than 35 years of age.
Keywords cervical cancer      human papilloma virus      cervical intraepithelial neoplasia      
Issue Date: 05 December 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0084-8     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I4/459
Parkin D M, Pisani P, Ferlay I. Global cancer statistics. CA Cancer J Clin, 1999, 49(1): 33–64

doi: 10.3322/canjclin.49.1.33
Li L D, Lu F Z, Zhang S W, Mu R, Sun X D, Huangpu X M, Sun J, Zhou Y S, Ouyang N H, Rao K Q, Chen Y D, Sun A M, Xue Z F, Xia Y. Themortality trend of malignant tumors in the past 20 years in Chinaand the recent prediction. Zhonghua ZhongLiu Za Zhi, 1997, 19(1): 3–9 (in Chinese)
Elliott P M, Tattersall M H, Coppleson M, Russell P, Coates A S, Solomon H J. Changing character of cervical cancer in young women. BMJ, 1989, 298(6685): 1451

doi: 10.1136/bmj.298.6685.1451
Wang Q J, Zhu W X, Xing X M, Li L. The Trend ofCancer Incidence in Urban Beijing from 1982 to 1997. Zhongguo Zhongliu, 2001, 10(9): 507–509 (in Chinese)
Woodman C B, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason T P, Young L S. Nature history of cervical human papillomavirus infectionin young women: a longitudinal cohorts study. Lancet, 2001, 357(9271): 1831–1836

doi: 10.1016/S0140-6736(00)04956-4
Richart R M. A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol, 1990, 75(1): 131–133
zur Hausen H. Condylomataacuminata and human genital cancer. CancerRes, 1976, 36(2 pt 2): 794
Belinson J, Qiao Y, Pretorius R, Zhang W, Keaton K, Elson P, Fischer C, Lorincz A, Zahniser D, Wilbur D, Pan Q, Li L, Biscotti C, Dawson A, Li A, Wu L, Ling Y, Ma C P, Yang X P. Prevalence of cervical cancer and feasibility of screening in ruralChina: a pilot study for the Shanxi Province Cervical Cancer ScreeningStudy. Int J Gynecol Cancer, 1999, 9(5): 411–417

doi: 10.1046/j.1525-1438.1999.99055.x
Franceschi S. TheIARC commitment to cancer prevention: the example of papillomavirusand cervical cancer. Recent Results CancerRes, 2005, 166: 277–297

doi: 10.1007/3-540-26980-0_18
Dai M, Bao Y P, Li N, Clifford G M, Vaccarella S, Snijders P J, Huang R D, Sun L X, Meijer C J, Qiao Y L, Franceschi S. Human papillomavirus infection in Shanxi Province, people'sRepublic of China: a population-based study. Br J Cancer, 2006, 95(1): 96–101

doi: 10.1038/sj.bjc.6603208
Li L K, Dai M, Clifford G M, Yao W Q, Arslan A, Li N, Shi J F, Snijders P J, Meijer C J, Qiao Y L, Franceschi S. Human papillomavirus infection in Shenyang City, people'sRepublic of China: A population-based study. Br J Cancer, 2006, 95(11): 1593–1597

doi: 10.1038/sj.bjc.6603450
Wu R F, Dai M, Qiao Y L, Clifford G M, Liu Z H, Arslan A, Li N, Shi J F, Snijders P J, Meijer C J, Franceschi S. Human papillomavirus infection in women in Shenzhen City,people's Republic of China, a population typical of recent Chineseurbanization. Int J Cancer, 2007, 121(6): 1306–1311

doi: 10.1002/ijc.22726
de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch F X. Worldwide prevalence and genotype distribution of cervicalhuman papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 2007, 7(7): 453–459

doi: 10.1016/S1473-3099(07)70158-5
Shi J F, Wu R F, Liu Z H, Zhou Q Z, Li N, Wu L N, Li Q, Wang Q, Liu B, Li R Z, Qiao Y L. Distribution of Human PapillomavirusTypes in Shenzhen Women. Zhongguo Yi XueKe Xue Yuan Xue Bao, 2006, 28(6): 832–836 (in Chinese)
Jin Y, Pan L Y. Role of high-risk human papillomavirustesting in the screening and management of cervical cancer precursors. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2007, 29(5): 691–696 (in Chinese)
Frega A, Stentella P, De Ioris A, Piazze J J, Fambrini M, Marchionni M, Cosmi E V. Young women,cervical intraepithelial neoplasia and human papillomavirus: riskfactors for persistence and recurrence. Cancer Lett, 2003, 196(2): 127–134

doi: 10.1016/S0304-3835(03)00218-0
Rombaldi R L, Serafini E P, Villa L L, Vanni A C, Baréa F, Frassini R, Xavier M, Paesi S. Infection with human papillomavirusesof sexual partners of women having cervical intraepithelial neoplasia. Braz J Med Biol Res, 2006, 39(2): 177–187

doi: 10.1590/S0100-879X2006000200003
Gupta A, Arora R, Gupta S, Prusty B K, Kailash U, Batra S, Das B C. Human papillomavirusDNA in urine samples of women with or without cervical cancer andtheir male partners compared with simultaneously collected cervical/penilesmear or biopsy specimens. J Clin Virol, 2006, 37(3): 190–194

doi: 10.1016/j.jcv.2006.07.007
Bardin A, Vaccarella S, Clifford G M, Lissowska J, Rekosz M, Bobkiewicz P, Kupryjańczyk J, Krynicki R, Jonska-Gmyrek J, Danska-Bidzinska A, Snijders P J, Meijer C J, Zatonski W, Franceschi S. Human papillomavirus infectionin women with and without cervical cancer in Warsaw, Poland. Eur J Cancer, 2008, 44(4): 557–564

doi: 10.1016/j.ejca.2007.12.001
Bosch F X, Manos M M, Muñoz N, Sherman M, Jansen A M, Peto J, Schiffman M H, Moreno V, Kurman R, Shah K V. Prevalenceof human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst, 1995, 87(11): 796–802

doi: 10.1093/jnci/87.11.796
Dehn D, Torkko K C, Shroyer K R. Human papillomavirus testing and molecular markers ofcervical dysplasia and carcinoma. Cancer, 2007, 111(1): 1–7

doi: 10.1002/cncr.22425
Clifford G M, Gallus S, Herrero R, Muñoz N, Snijders P J, Vaccarella S, Anh P T, Ferreccio C, Hieu N T, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin H R, Sukvirach S, Thomas J O, Tunsakul S, Meijer C J, Franceschi S; IARC HPV Prevalence SurveysStudy Group. Worldwide distribution of human papillomavirus typesin cytologically normal women in the International Agency for Researchon Cancer HPV prevalence surveys: a pooled analysis. Lancet, 2005, 366(9490): 991–998

doi: 10.1016/S0140-6736(05)67069-9
Bell M C, Schmidt-Grimminger D, Patrick S, Ryschon T, Linz L, Chauhan S C. There is a high prevalence of human papillomavirus infectionin American Indian women of the Northern Plains. Gynecol Oncol, 2007, 107(2): 236–241

doi: 10.1016/j.ygyno.2007.06.007
[1] Tian Wang, Yan Li, Abidan Tuerhanjiang, Wenwen Wang, Zhangying Wu, Ming Yuan, Shixuan Wang. Correlation of Twist upregulation and senescence bypass during the progression and metastasis of cervical cancer[J]. Front Med, 2014, 8(1): 106-112.
[2] Shuang LI, Yu-Han MENG, Hu TING, Jian SHEN, Ding MA. Clinical significance of human papilloma virus infection in the cervical lesions[J]. Front Med Chin, 2010, 4(3): 264-270.
[3] Shao-Ming WANG, Jing LI, You-Lin QIAO. HPV prevalence and genotyping in the cervix of Chinese women[J]. Front Med Chin, 2010, 4(3): 259-263.
[4] Zhou-Fang XIONG MD, Wei-Hong DONG MD, Ze-Hua WANG MD, . Non-closure of the peritoneum and subcutaneous tissue at radical hysterectomy: A randomized controlled trial[J]. Front. Med., 2010, 4(1): 112-116.
[5] Guocheng LIU MD, Shouhua YANG MD, Zehua WANG MD, . The relationship between platelet-derived growth factor expression and angiogenesis/lymphangiogenesis in cervical cancer[J]. Front. Med., 2009, 3(4): 447-451.
[6] Yuan ZHANG MD , Xiaoyan ZHANG MM , Yanhui LI MM , Xuan DU MM , Zehua WANG MD, PhD , Hongbo WANG MD , . Effects of phosphatidylinositol 3-kinase inhibitor on human cervical carcinoma cells [J]. Front. Med., 2009, 3(3): 341-346.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed